Then, we detected the percentage of PHH3-positive M-phase tumour cells after SHCBP1 knockdown combined with low-dose ETOP or CDDP treatment by immunostaining assay, flow cytometry, and western blotting analysis (Fig. 7A–D). This evidence concerns the gene SHCBP1 and neoplasm.